Related Experiment Videos
Targeting the mercapturic acid pathway and vicenin-2 for prevention of prostate cancer
Sharad S Singhal1, Divya Jain2, Preeti Singhal3
1Department of Molecular Medicine, Beckman Research Institute of City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA 91010, United States.
Abstract:
Prostate cancer (CaP) is often androgen-sensitive malignancy and regresses upon inhibition of androgen signaling. However, CaP, nearly always develops androgen resistance and progresses to aggressive and lethal androgen-independent CaP, which lacks satisfactory therapy. For metastatic CaP, patients are often treated with Taxotere (docetaxel), a cytoskeleton-targeted chemotherapy drug, that provides transient palliative benefit but to which patients rapidly develop drug-resistance. Combination chemotherapy may be used instead, but is more toxic and adds little clinically relevant benefit over docetaxel. Therefore, novel strategies to enhance docetaxel efficacy are needed to effectively treat patients with metastatic CaP. The mercapturic acid pathway, which metabolizes genotoxic and pro-apoptotic toxins, is over-expressed in CaP and plays an important role in carcinogenesis, metastasis and therapy-resistance of CaP. Vicenin-2, a flavonoid derived from Tulsi (holy basil) as an active compound, inhibits the growth of CaP and increases the anti-tumor activity of docetaxel in-vitro and in-vivo. Taken together, the combination of vicenin-2 and docetaxel could be highly effective in the treatment of advanced and metastatic CaP due to their multi-targeting anti-tumor potential.
Insights
Vicenin-2, a compound from holy basil, enhances docetaxel chemotherapy for advanced prostate cancer (CaP). This combination shows promise for treating aggressive CaP by overcoming drug resistance and improving patient outcomes.
Area of Science:
- Oncology
- Pharmacology
- Natural Products Chemistry
Background:
- Prostate cancer (CaP) is typically androgen-sensitive but often develops resistance to androgen signaling inhibition.
- Metastatic CaP is treated with docetaxel chemotherapy, but rapid drug resistance limits its efficacy.
- The mercapturic acid pathway is overexpressed in CaP, contributing to progression and therapy resistance.
Purpose of the Study:
- To investigate the potential of vicenin-2, a flavonoid from Tulsi (holy basil), to enhance docetaxel efficacy in prostate cancer.
- To explore novel therapeutic strategies for advanced and metastatic CaP by targeting multiple pathways.
Main Methods:
- In vitro and in vivo studies were conducted to evaluate the anti-tumor activity of vicenin-2 alone and in combination with docetaxel.
- The effects on prostate cancer cell growth and docetaxel resistance were assessed.
Main Results:
- Vicenin-2 demonstrated direct inhibition of prostate cancer cell growth.
- The combination of vicenin-2 and docetaxel significantly increased anti-tumor activity compared to docetaxel alone.
- This combination therapy showed potential in overcoming docetaxel resistance in preclinical models.
Conclusions:
- Vicenin-2, a natural compound, can enhance the efficacy of docetaxel in treating prostate cancer.
- The combination of vicenin-2 and docetaxel offers a promising multi-targeting strategy for advanced and metastatic CaP.
- Further clinical investigation is warranted to validate these findings for patient treatment.